GRI — Stock Film
STOCK FILMSCENE 1/11GRI · $1.51
Stock Expert AI presents
GRI
GRI Bio, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
GRI Bio, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 4 employees. Now — the numbers.

on the stock market since 2021
4 employees
$136K market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $71K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 6 did the company clear?
2 / 6
EXPECTATIONS MET OR BEATEN
2
Nov 2024
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
2 TIMES IN THE LAST 6 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
19
very weak

Clearly below the class average.

FINANCIAL STRENGTH
73
strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
16
very weak

Clearly below the class average.

PRICE MOMENTUM
10
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 18 buys and 0 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.49 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $12.0M against $0 in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, GRI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: GRI is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film